DMII
DMII
NASDAQ · N/A

Drugs Made In America Acquis

$9.97
+0.00 (+0.00%)
As of Mar 25, 2:35 PM ET ·
Financial Highlights (FY 2025)
Revenue
294.92M
Net Income
26.28M
Gross Margin
63.8%
Profit Margin
8.9%
Rev Growth
+17.5%
D/E Ratio
0.63
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 63.8% 63.8% 63.8%
Operating Margin 13.0% 12.5% 13.2%
Profit Margin 8.9% 9.3% 11.0%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 294.92M 307.45M 258.08M
Gross Profit 188.10M 196.09M 164.61M
Operating Income 38.37M 38.48M 34.14M
Net Income 26.28M 28.57M 28.41M
Gross Margin 63.8% 63.8% 63.8%
Operating Margin 13.0% 12.5% 13.2%
Profit Margin 8.9% 9.3% 11.0%
Rev Growth +17.5% +6.4% -5.2%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 263.77M 325.63M 306.48M
Total Equity 417.39M 374.79M 447.00M
D/E Ratio 0.63 0.87 0.69
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 56.56M 62.55M 47.02M
Free Cash Flow 16.46M 18.79M 20.07M